Clinical Trial Update: PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

View source ↗

Summary

This clinical trial update describes a study evaluating PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy, with or without transarterial chemoemboliza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-angiogenic therapy
• PD-1/PD-L1 inhibitors (PD-1/PD-L1 inhibitors)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Status: NOT_YET_RECRUITING